Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0BA6T
|
||||
| Former ID |
DAP000226
|
||||
| Drug Name |
Methyldopa
|
||||
| Synonyms |
AMD; Aldomet; Aldometil; Aldomin; Alphamethyldopa; Baypresol; Becanta; Dopamet; Dopamethyperpax; Dopatec; Dopegit; Dopegyt; Dopergit; Grospisk; Hyperpax; Hypolag; Medomet; Medopa; Medopal; Medopren; Methoplain; Methyldopum; Metildopa; Novomedopa; Presinol; Presolisin; Sedometil; Sembrina; Alpha medopa; Methyl dopa; Methyldopa anhydrous; Aldoril D30; Aldoril D50; Bayer 1440 L; LT00847269; MK 351; Aldomet (TN); Aldoril (TN); Alpha-Methyl dopa; Alpha-Methyldihydroxyphenylalanine; Alpha-Methyldopa; Apo-Methyldopa; Dopamet (TN); Dopegyt (TN); L-Methyl Dopa; L-Methyldopa; METHYL DOPA (SEE ALSO METHYL DOPA SESQUIHYDRATE); MK-351; Methyldopa (INN); Methyldopa (anhydrous); Methyldopum [INN-Latin]; Metildopa [INN-Spanish]; Mk. b51; Nr.C 2294; Nu-Medopa; Alpha-Methyldopa (VAN); L-alpha-Methyl DOPA; L-alpha-Methyldopa; Methyl-L-dopa; Aldoril, Dopamet, Dopegyt, Methyldopa; L-(alpha-Md); Methyldopa (L,-); Alpha-Methyl-L-3,4-dihydroxyphenylalanine; L-alpha-Methyl-3,4-dihydroxyphenylalanine; L-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Alpha-Methyl-beta-(3,4-dihydroxyphenyl)-L-alanine; L(-)-beta-(3,4-Dihydroxyphenyl)-alpha-methylalanine; L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic acid; L-(-)-3-(3,4-Dihydroxyphenyl)-2-methylalanine; L-(-)-alpha-Methyl-beta-(3,4-dihydroxyphenyl)alanine; (-)-3-(3,4-Dihydroxyphenyl)-2-Methyl-L-Alanine Sesqui-Hydrate; (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; (S)-(-)-alpha-Methyldopa; 3-(3,4-DIHYDROXYPHENYL)-2-METHYL-L-ALANINE; 3-Hydroxy-.alpha.-methyl-L-tyrosine; 3-Hydroxy-alpha-methyl-L-tyrosine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Antihypertensive Agents
|
||||
| Company |
Ivax pharmaceutical
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C10H13NO4
|
||||
| InChI |
InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1
|
||||
| InChIKey |
CJCSPKMFHVPWAR-JTQLQIEISA-N
|
||||
| CAS Number |
CAS 555-30-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9403, 597355, 7979942, 8139902, 8149423, 8175761, 10321684, 11113581, 11335317, 11360556, 11363831, 11366393, 11368955, 11371621, 11373686, 11377117, 11461528, 11466354, 11467474, 11484792, 11485988, 11488884, 11490317, 11491869, 11494751, 14748911, 17405414, 26611818, 26679555, 34704829, 46508535, 47290999, 47440113, 47736324, 47736325, 47810607, 48034965, 48110315, 48184859, 48416254, 48423673, 49698436, 49854436, 50104474, 50104475, 50104476, 50104477, 50970645, 53777959, 53790662
|
||||
| SuperDrug ATC ID |
C02AB01
|
||||
| SuperDrug CAS ID |
cas=000555306
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Agonist | [536417] | |
| References | |||||
| Ref 468270 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5217). | ||||
| Ref 538218 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070075. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.